title: [Autologous hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma: a retrospective study].
abstract: The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with diffuse large B-cell lymphoma (DLBCL), and analyse the factors influencing prognosis. The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), and relapse rate were retrospectively analyzed. The results showed that the median follow-up time was 40 months after transplantation. Three-year cumulative OS and PFS were 70.6% and 66.4% respectively, 5-year cumulative OS and PFS were 70.6% and 63.8% respectively, and TRM was 7.2%. One-year and three-year cumulative relapse rate were 16.5% and 23.7% respectively. Univariate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis (P < 0.05). It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL, especially for the young patients or patients with better remission.
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Lu
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Huang
authors.forename: Yue-Lu
authors.initials: YL
authors.lastname: Guo
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Zhao
authors.forename: Ning
authors.initials: N
authors.lastname: Lu
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Zhu
authors.forename: Quan-Shun
authors.initials: QS
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult